CN107625752A - A kind of levo-oxiracetam spansule of high income and preparation method thereof - Google Patents

A kind of levo-oxiracetam spansule of high income and preparation method thereof Download PDF

Info

Publication number
CN107625752A
CN107625752A CN201610554563.4A CN201610554563A CN107625752A CN 107625752 A CN107625752 A CN 107625752A CN 201610554563 A CN201610554563 A CN 201610554563A CN 107625752 A CN107625752 A CN 107625752A
Authority
CN
China
Prior art keywords
parts
levo
oxiracetam
whole grain
sieves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610554563.4A
Other languages
Chinese (zh)
Inventor
叶雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Runze Pharmaceutical Co Ltd
Original Assignee
Chongqing Runze Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Runze Pharmaceutical Co Ltd filed Critical Chongqing Runze Pharmaceutical Co Ltd
Priority to CN201610554563.4A priority Critical patent/CN107625752A/en
Publication of CN107625752A publication Critical patent/CN107625752A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

A kind of levo-oxiracetam spansule of high income is made up of following supplementary material:1 part of levo-oxiracetam, 1.5 parts ~ 2.2 parts of lactose, 1.2 parts ~ 1.9 parts of HPMC K4M, 0.8 part ~ 1.5 parts of Brazil wax, 0.3 part ~ 0.8 part of octadecanol, 0.5 ~ 1.1 part of calcium monohydrogen phosphate, 0.8 ~ 1.5 part of superfine silica gel powder, 2.5 parts ~ 3.5 parts of 5% ~ 10% PVP K30 ethanol solution;Bisque is few after levo-oxiracetam spansule of the present invention has particle whole grain, and product yield is up to 96.8%, and rate of release is slow, and deenergized period, this product stability was good up to 12 hours, and storage process capsule will not be sticked together, and shelf life is up to 24 months.

Description

A kind of levo-oxiracetam spansule of high income and preparation method thereof
Technical field
The invention mainly relates to pharmaceutical technology field, and in particular to a kind of levo-oxiracetam spansule of high income and Its preparation method.
Background technology
It is a kind of new medicine for central nervous system for promoting study, strengthening memory that cereboactive drug, which is also known as cereboactive drug,. Nootropics requires that selection index system in cerebral cortex, has selection activation, protection and promotes damaged nerve cell functional rehabilitation Feature.Different from other neurologic agents be a little their above-mentioned effect not by network or olfactory bulb, but directly Act on cortex.Behavior is neither influenceed, also without calm excitation, therefore such medicine has caused the extensive concern of people and emerging Interest, it is also growing day by day to the demand of such medicine.
Oxiracetam (oxiracetam, CAS No.:62613-82-5) the entitled 4- hydroxyls -2- OXo-1-pyrrolidines of chemistry Acetamide, (compound is disclosed in the anti anoxia class cereboactive drug synthesized first in 1974 for Italian ISFS.P.A companies US4118396), it is ring GABOB derivatives, Phosphorylcholine and phosphatidyl ethanolamine can be promoted to synthesize, promotes brain metabolism, through blood brain Barrier, there is stimulation to specific nervous centralis road, intelligence and memory can be improved, to cerebrovascular disease, brain trauma, brain Knurl, intracranial infection, brain degenerative disease etc. also have the effect of preferable, and the drug toxicity is extremely low, no mutagenesis and carcinogenic work With and genotoxicity.Giorgio et al. discloses the chemical constitution and preparation method of Oxiracetam in US4118396, Chiodini et al. is disclosed in W09306826A, and clinical effectiveness proves that the drug effect of the Oxiracetam of S configurations (left-handed) is better than R structures Type (dextrorotation), Oxiracetam and levo-oxiracetam structure are as follows.
Existing levo-oxiracetam spansule is primarily present release and can not preferably controlled, it is impossible to reaches sustained release preparation It is required that particle bisque is more after whole grain, product yield is low, the technical problem such as storage process capsule connecting block easy to stick.
The content of the invention
It is an object of the invention to provide a kind of release is good, levo-oxiracetam spansule of high income.
Another object of the present invention is to provide the preparation method of above-mentioned levo-oxiracetam spansule.
The purpose of the present invention is realized by following technical measures:
A kind of levo-oxiracetam spansule of high income, it is characterised in that it be using levo-oxiracetam as raw material, A certain amount of sustained-release matrix material, retarding agent, lubricant and adhesive is added to be made;Wherein described sustained-release matrix material is hydroxyl Third methylcellulose, ethyl cellulose, polyethylene, polypropylene, polysiloxanes, polyoxyethylene, lactose, fructose, sucrose, mannose One or more in alcohol, sodium alginate, agar, chitin, galactolipin;The retarding agent is fat, beeswax, babassu One kind or several in wax, hydrogenated vegetable oil, stearyl alcohol, glycerin monostearate, superfine silica gel powder, calcium monohydrogen phosphate, microcrystalline cellulose Kind;The lubricant is the one or more in magnesium stearate, talcum powder, silica, octadecanol;Adhesive therefor is second Any of alcoholic solution, starch slurry, sucrose solution, water, PVP K30 ethanol solution.
Inventor has found that specific supplementary material species coordinates specific supplementary material consumption proportion relation in research process, Coordinate specific preparation method again, may be such that above-mentioned levo-oxiracetam spansule release time be up to 12 hours, whole grain it Particle bisque is few afterwards, and product yield is high, storage process capsule will not adhesion caking, above-mentioned levo-oxiracetam spansule, its It is characterised by, it is made up of the supplementary material of following weight proportion:1 part of levo-oxiracetam, 1.5 parts~2.2 parts of lactose, hydroxypropyl 1.2 parts~1.9 parts of methylcellulose K4M, 0.8 part~1.5 parts of Brazil wax, 0.3 part~0.8 part of octadecanol, phosphoric acid hydrogen 0.5~1.1 part of calcium, 0.8~1.5 part of superfine silica gel powder, 2.5 parts of the PVP K30 ethanol solution that mass fraction is 5%~10%~ 3.5 part;Take levo-oxiracetam, lactose, HPMC K4M, Brazil wax, calcium monohydrogen phosphate, the micro mist of recipe quantity Silica gel puts co-grinding in mixing mill and (is all sieved by No. 5 into fine powder and can must not be less than total amount by the amounts of No. 6 sieves 95%), sieve;PVP K30 ethanol solution is added, with 18 mesh sieve mixing granulations, by manufactured wet granular, is placed in hot-air oven In, 40~60 DEG C of temperature is set, dried to pellet moisture≤3%, whole grain (crosses 24 mesh sieves), standby;Octadecanol crushed 100 mesh sieves, add in the particle after whole grain, with three-dimensional motion mixer mixing 10min~20min.
Further, in order that particle bisque is less after obtaining levo-oxiracetam spansule whole grain, product yield is higher, Above-mentioned levo-oxiracetam spansule, it is characterised in that it is made by the supplementary material of following weight proportion:Left-handed Aura west Smooth 1 part, 1.8 parts~2.1 parts of lactose, 1.5 parts~1.7 parts of HPMC K4M, 1.1 parts~1.3 parts of Brazil wax, 0.4 part~0.6 part of octadecanol, 0.7~1.0 part of calcium monohydrogen phosphate, 1.1~1.3 parts of superfine silica gel powder, mass fraction be 5%~ 2.7 parts~3.3 parts of 10% PVP K30 ethanol solution;Take the levo-oxiracetam, lactose, hydroxypropyl methylcellulose of recipe quantity Plain K4M, Brazil wax, calcium monohydrogen phosphate, superfine silica gel powder are put co-grinding in mixing mill and (all sieved into fine powder by No. 5 And can by No. 6 sieve amounts must not be less than total amount 95%), sieving;PVP K30 ethanol solution is added, is mixed with 18 mesh sieves Granulation, manufactured wet granular is placed in hot-air oven, sets 40~60 DEG C of temperature, is dried to pellet moisture≤3%, whole grain (crossing 24 mesh sieves), it is standby;Octadecanol be crushed into 100 mesh sieves, add in the particle after whole grain, mixed with three-dimensional motion mixer Close 10min~20min.
The preparation method of the levo-oxiracetam spansule of a kind of high income, it is characterised in that it is as follows It is obtained:
1. supplementary material pre-treatment:Take the main ingredient, sustained-release matrix material and retarding agent of recipe quantity to put in mixing mill to mix Conjunction is ground into fine powder (all sieved by No. 5 and can must not be less than the 95% of total amount by the amounts of No. 6 sieves), sieving;
2. granulation:Adhesive is added, with 18 mesh sieve mixing granulations, manufactured wet granular is placed in hot-air oven, is set 40~60 DEG C of temperature, dry to pellet moisture≤3%, whole grain (crosses 24 mesh sieves), standby;
It is 3. total mixed:Lubricant be crushed into 100 mesh sieves, add in the particle after whole grain, mixed with three-dimensional motion mixer 10min~20min;
4. filling:Filled with fully-automatic capsule filler, adjust loading amount 0.5g/ grains, whole filling process need to control relatively Humidity is below 50%;
It is 5. aluminum-plastic packaged:Dispensed with aluminium-plastic bubble plate packing machine, per plate 10, operation room relative humidity have to be lower than 50%;
6. outsourcing produces.
The present invention has following beneficial effect:
Bisque is few after levo-oxiracetam spansule of the present invention has particle whole grain, and product yield is up to 96.8%, releases It is slow to put speed, deenergized period was up to 12 hours, therefore this product can reduce compared with conventional formulation and take number, take once a day; Meanwhile this product stability is good, storage process capsule will not be sticked together, and shelf life is up to 24 months, preparation technology simple possible, It is worth marketing.
Embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be that following examples are only used It is further described in the present invention, it is impossible to limiting the scope of the invention is interpreted as, without departing substantially from spirit of the invention In the case of essence, the modifications or substitutions made to the inventive method, step or condition belong to the scope of the present invention.
Embodiment 1
A kind of levo-oxiracetam spansule of high income, is made according to the following steps:
Preparation process:
1. supplementary material pre-treatment:Take the levo-oxiracetam of recipe quantity, lactose, HPMC K4M, babassu Wax, calcium monohydrogen phosphate, superfine silica gel powder put co-grinding in mixing mill into fine powder (all by No. 5 sieves and can be by No. 6 sieves Must not measure less than total amount 95%), sieving;
2. granulation:PVP K30 ethanol solution is added, with 18 mesh sieve mixing granulations, by manufactured wet granular, is placed in hot blast In baking oven, 40~60 DEG C of temperature is set, dried to pellet moisture≤3%, whole grain (crosses 24 mesh sieves), standby;
It is 3. total mixed:Octadecanol be crushed into 100 mesh sieves, add in the particle after whole grain, mixed with three-dimensional motion mixer Close 10min~20min;
4. filling:Filled with fully-automatic capsule filler, adjust loading amount 0.5g/ grains, whole filling process need to control relatively Humidity is below 50%;
It is 5. aluminum-plastic packaged:Dispensed with aluminium-plastic bubble plate packing machine, per plate 10, operation room relative humidity have to be lower than 50%;
6. outsourcing produces.
In order to be better understood from the present invention, having for invention medicine is expanded on further below by way of stability test of the present invention Beneficial effect, rather than limitation of the present invention.
Experiment one:Yield calculates
1. test material:Gained finished product in the preparation process of embodiment 1
2. test method:With quality obtained by the quality of inventory and finished product, product yield is calculated;
3. result of the test:It see the table below
Name of product Inventory Packaging material weight Finished weight Yield
Embodiment 1 500.2g 29.2g 512.6g 96.8%
4. conclusion (of pressure testing):It can be seen that product yield is up to 96.8% by upper table result of the test.
Experiment two:Drug release determination
1. test material:The test specimen of Example 1
2. test method:Spansule obtained above is taken as sample, according to release inspection technique (Chinese Pharmacopoeia 2010 editions Two the second methods of annex X D), using the device of the method for dissolution method second, using water 900ml as dissolution medium, rotating speed is every 100 turns of minute, operate in accordance with the law, through 1,2,4,6,8,12 hour, take release solution 10ml, filtered with 0.45 μm of miillpore filter, Subsequent filtrate is taken as need testing solution, and supplements dissolution medium 10ml in process container in time.Another precision weighs left-handed Aura Western smooth reference substance about 10mg is put in 25ml measuring bottles, is dissolved with water and is diluted to scale, shaken up, as reference substance solution.Essence respectively It is close to measure above-mentioned reference substance solution and each 20 μ l of need testing solution, determined according to the chromatographic condition of assay.Calculate every Release (refers to Accumulation dissolution).
3. result of the test:The measurement result of the release of spansule sample of the present invention see the table below
4. conclusion (of pressure testing):Levo-oxiracetam spansule main ingredient levo-oxiracetam discharges into slow, release time length Up to 12 hours, the requirement of sustained release preparation can be met.
Experiment three:A kind of levo-oxiracetam spansule stability experiment of the present invention
Experiment material:
Levo-oxiracetam spansule:It is made for embodiment 1.
Acceleration study method:Levo-oxiracetam spansule made from embodiment 1 is packed by listing, puts Acceleration study In case, certain time sampling, investigation project is tested.
Acceleration study temperature:40±2℃
Humidity:RH75% ± 5%
Investigate the time:0th, 1,2,3, June
Inspection target:
Character, moisture, relevant material, release, content, microbial limit accelerated test stability record:
Acceleration study result shows:Acceleration sample in June is suitable with 0 month sample items Testing index quality, shows that this product adds Speed is tested June, and quality keeps stable, and this product stability is preferable.
Long-term experiment method:Levo-oxiracetam spansule made from embodiment 1 is packed by listing, puts and keeps sample for a long time In case, certain time sampling, investigation project is tested.
Acceleration study temperature:25±2℃
Humidity:RH60% ± 10%
Investigate the time:0th, 3,6,9,12,18 months
Character, moisture, relevant material, release, content, microbial limit
Long term test stability records:
Long term test shows:24 months characters of this product long term test, moisture, relevant material, release, content, microorganism Limit meets every relevant regulations of production quality standard draft without significant changes.24 lunar geology of this product long term test Amount is stable, therefore minimum 24 months of this product term of validity, and long term test is still during investigation is continued.
Embodiment 2
A kind of levo-oxiracetam spansule, is made according to the following steps:
Preparation process:It is made according to the preparation technology of embodiment 1.Tested by the test method of embodiment 1, divide yield meter Calculate result and show that product yield is up to 95.3%, drug release determination result of the test shows levo-oxiracetam spansule in slow Release, release time are up to 12 hours, can meet the requirement of sustained release preparation, and stability test result shows to accelerate 6 lunar sample qualities Amount is stable, does not find capsule adhesion phenomenon, long-term 24 months steady qualities, does not find capsule adhesion phenomenon, therefore this product term of validity At least 24 months.
Embodiment 3
A kind of levo-oxiracetam spansule, is made according to the following steps:
Preparation process:It is made according to the preparation technology of embodiment 1.Tested by the test method of embodiment 1, divide yield meter Calculate result and show that product yield is up to 95.3%, drug release determination result of the test shows levo-oxiracetam spansule in slow Release, release time are up to 12 hours, can meet the requirement of sustained release preparation, and stability test result shows to accelerate 6 lunar sample qualities Amount is stable, does not find capsule adhesion phenomenon, long-term 24 months steady qualities, does not find capsule adhesion phenomenon, therefore this product term of validity At least 24 months.
Embodiment 4-6:A kind of levo-oxiracetam spansule, is prepared, preparation side by the supplementary material of following weight Method is the same as embodiment 1:
It is made according to the preparation technology of embodiment 1.Tested by the test method of embodiment 1, the yield point of embodiment 4,5,6 Not Wei 97.2%, 94.1%, 95.8%, the drug release determination result of the test of embodiment 4,5,6 show levo-oxiracetam be sustained glue Capsule can meet the requirement of sustained release preparation, the stability of embodiment 4,5,6 in slowly release, release time up to 12 hours Result of the test shows to accelerate June sample quality stable, and sample does not occur capsule adhesion phenomenon, long-term 24 months steady qualities, Sample does not occur capsule adhesion phenomenon, therefore this product term of validity at least 24 months.

Claims (3)

1. the levo-oxiracetam spansule of a kind of high income, it is characterised in that it is by the supplementary material of following weight proportion Composition:1 part of levo-oxiracetam, 1.5 parts ~ 2.2 parts of lactose, 1.2 parts ~ 1.9 parts of HPMC K4M, Brazil wax 0.8 part ~ 1.5 parts, 0.3 part ~ 0.8 part of octadecanol, 0.5 ~ 1.1 part of calcium monohydrogen phosphate, 0.8 ~ 1.5 part of superfine silica gel powder, mass fraction For 5% ~ 10% 2.5 parts ~ 3.5 parts of PVP K30 ethanol solution;Take the levo-oxiracetam, lactose, hydroxypropyl of recipe quantity fine Tie up plain K4M, Brazil wax, calcium monohydrogen phosphate, superfine silica gel powder and put in mixing mill co-grinding into fine powder(All pass through No. 5 Sieve and can must not be less than the 95% of total amount by the amounts of No. 6 sieves), sieving;PVP K30 ethanol solution is added, is mixed with 18 mesh sieves Granulation, manufactured wet granular is placed in hot-air oven, sets 40 ~ 60 DEG C of temperature, is dried to pellet moisture≤3%, whole grain(Cross 24 mesh sieves), it is standby;Octadecanol be crushed into 100 mesh sieves, add in the particle after whole grain, mixed with three-dimensional motion mixer 10min~20min。
2. levo-oxiracetam spansule as claimed in claim 1, it is characterised in that it is by the original of following weight proportion Auxiliary material is made:1 part of levo-oxiracetam, 1.8 parts ~ 2.1 parts of lactose, 1.5 parts ~ 1.7 parts of HPMC K4M, cohune 1.1 parts ~ 1.3 parts of palmitic acid wax, 0.4 part ~ 0.6 part of octadecanol, 0.7 ~ 1.0 part of calcium monohydrogen phosphate, 1.1 ~ 1.3 parts of superfine silica gel powder, quality Fraction is 5% ~ 10% 2.7 parts ~ 3.3 parts of PVP K30 ethanol solution;Take the levo-oxiracetam, lactose, hydroxypropyl first of recipe quantity Base cellulose K4M, Brazil wax, calcium monohydrogen phosphate, superfine silica gel powder put in mixing mill co-grinding into fine powder(It is all logical Cross No. 5 sieves and can must not be less than the 95% of total amount by the amount of No. 6 sieves), sieving;PVP K30 ethanol solution is added, with 18 mesh Mixing granulation is sieved, manufactured wet granular is placed in hot-air oven, 40 ~ 60 DEG C of temperature is set, is dried to pellet moisture≤3%, Whole grain(Cross 24 mesh sieves), it is standby;Octadecanol be crushed into 100 mesh sieves, add in the particle after whole grain, mixed with three-dimensional motion Machine mixing 10min ~ 20min.
3. the preparation method of levo-oxiracetam spansule as claimed in claim 1 or 2, it is characterised in that it is by such as Made from lower step:
A. supplementary material pre-treatment:The main ingredient, sustained-release matrix material and retarding agent of recipe quantity is taken to put mixed powder in mixing mill It is broken into fine powder(All sieved by No. 5 and can must not be less than the 95% of total amount by the amounts of No. 6 sieves), sieving;
B. pelletize:Adhesive is added, with 18 mesh sieve mixing granulations, manufactured wet granular is placed in hot-air oven, temperature is set 40 ~ 60 DEG C, dry to pellet moisture≤3%, whole grain(Cross 24 mesh sieves), it is standby;
C. it is total mixed:Lubricant be crushed into 100 mesh sieves, added in the particle after whole grain, with three-dimensional motion mixer mixing 10min ~20min;
D. fill:Filled with fully-automatic capsule filler, adjust loading amount 0.5g/ grains, whole filling process need to control relative humidity Below 50%;
E. it is aluminum-plastic packaged:Dispensed with aluminium-plastic bubble plate packing machine, per plate 10, operation room relative humidity have to be lower than 50%;
F. outsourcing produces.
CN201610554563.4A 2016-07-14 2016-07-14 A kind of levo-oxiracetam spansule of high income and preparation method thereof Withdrawn CN107625752A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610554563.4A CN107625752A (en) 2016-07-14 2016-07-14 A kind of levo-oxiracetam spansule of high income and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610554563.4A CN107625752A (en) 2016-07-14 2016-07-14 A kind of levo-oxiracetam spansule of high income and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107625752A true CN107625752A (en) 2018-01-26

Family

ID=61112368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610554563.4A Withdrawn CN107625752A (en) 2016-07-14 2016-07-14 A kind of levo-oxiracetam spansule of high income and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107625752A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599083A (en) * 2013-12-06 2014-02-26 重庆东泽医药科技发展有限公司 Levo-oxiracetam slow-release tablet and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599083A (en) * 2013-12-06 2014-02-26 重庆东泽医药科技发展有限公司 Levo-oxiracetam slow-release tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
CN105055359B (en) (S) pyrrolidine acetamide sustained release tablets of 4 hydroxyl, 2 oxo 1 and preparation method thereof
CN107625752A (en) A kind of levo-oxiracetam spansule of high income and preparation method thereof
CN104739796B (en) A kind of Oxiracetam tablet and preparation method thereof
CN107625753A (en) A kind of levo-oxiracetam spansule of high income and preparation method thereof
CN107638412A (en) A kind of levo-oxiracetam spansule of high income and preparation method thereof
CN107648204A (en) Good levo-oxiracetam spansule of a kind of mobility of particle and preparation method thereof
CN107661313A (en) A kind of levo-oxiracetam spansule and preparation method thereof
CN107625748A (en) Good levo-oxiracetam spansule of a kind of stability and preparation method thereof
CN107648203A (en) Good levo-oxiracetam spansule of a kind of mobility of particle and preparation method thereof
CN106955275B (en) A kind of levo-oxiracetam spansule and preparation method thereof that stability is good
CN107625751A (en) Good levo-oxiracetam spansule of a kind of stability and preparation method thereof
CN106511311A (en) Levo-oxiracetam sustained-release capsule with good particle mobility and preparation method of levo-oxiracetam sustained-release capsule
CN107638411A (en) A kind of levo-oxiracetam spansule and preparation method thereof
CN107648201A (en) Good levo-oxiracetam spansule of a kind of mobility of particle and preparation method thereof
CN106955274B (en) - 2 oxo-1-pyrrolidine ethanamide spansule of one kind (S) -4- hydroxyls and preparation method thereof
CN107625746A (en) A kind of levo-oxiracetam spansule and preparation method thereof
CN107661310A (en) A kind of levo-oxiracetam capsule for being sustained release and preparation method thereof
CN106511305A (en) L-oxiracetam slow release capsule with high yield and preparation method thereof
CN107661308A (en) A kind of high income(S)Pyrrolidine acetamide spansule of 4 hydroxyl, 2 oxo 1 and preparation method thereof
CN106511306B (en) Levo-oxiracetam sustained-release capsule and preparation method thereof
CN107638414A (en) A kind of (S) -4- hydroxyls -2 oxo-1-pyrrolidine ethanamide spansule of high income and preparation method thereof
CN106511304A (en) L-oxiracetam sustained release capsule with high stability, and preparation method thereof
CN107661315A (en) A kind of levo-oxiracetam capsule for being sustained release and preparation method thereof
CN106511307B (en) It is a kind of(S)- 2 oxo-1-pyrrolidine ethanamide spansule of -4- hydroxyls and preparation method thereof
CN106511310B (en) (S) -4-hydroxy-2 oxo-1-pyrrolidine acetamide sustained-release capsule with good stability and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20180126